In view of this cancer research has been investigating novel therapeutical options, in special, an AACR abstract introduces CRD-799, a novel oral inhibitor that targets not only GCN2 but also two other related stress-response kinases, HRI and PERK. Here, EIF2AK3 is linked to cancer.